Search

A report from the University of Toronto discusses the challenges in diagnosing and treating chronic inflammatory demyelinating polyneuropathy (CIDP) in children. CIDP is a rare autoimmune neurological disorder that affects both pediatric and adult populations. The report highlights the difficulty in differentiating CIDP from inherited neuropathies, such as Charcot-Marie-Tooth disease, and emphasizes the need for genetic testing in patients who do not respond to conventional CIDP therapies. Current treatment options for CIDP include intravenous immunoglobulins, corticosteroids, and plasmapheresis, but the report suggests that novel therapies are needed for patients who do not respond to standard treatments or experience adverse effects. [Extracted from the article]